DROPERIDOL

Post-LOE

droperidol

Bristol Myers Squibb

ANDAINJECTIONINJECTABLE

Approved

Nov 1986

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DROPERIDOL (droperidol) by Bristol Myers Squibb is clinical pharmacology droperidol produces marked tranquilization and sedation. Approved for nausea, vomiting associated with surgical, diagnostic procedures. First approved in 1986.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in…

Indications (3)

nausea

Worked on DROPERIDOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.